Exact Sciences Corporation

Exact Sciences Corporation has been granted 72 US utility patents between 2015 and 2025, placing Exact Sciences Corporation at rank #4,817 across all assignees tracked by PlainPatent. This portfolio spans 15 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.2 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, Exact Sciences Corporation is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 57.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 44 grants, compared with 28 in the 2015–2019 window — a +57% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Exact Sciences Corporation's 14.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 15 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Exact Sciences Corporation against peers pursuing similar technology classes.